Takeda Cancer Drug Extends Survival in Phase 3 Gastric Cancer Trial

MT Newswires Live10-23

Takeda Pharmaceutical (TAK) said Friday its experimental drug, arcotatug tavatecan, met both primary goals in a phase 3 trial involving certain patients with advanced gastric or gastroesophageal junction cancer.

The company said the study showed that patients receiving the drug lived a median of 10.2 months, compared with 6.9 months for those receiving standard treatment.

Median progression-free survival was 7.1 months versus 3.1 months, respectively, the company said.

Takeda said the drug also achieved a 37.4% response rate, compared with 7.7% for standard treatment.

The company said it plans to use the results to support a regulatory filing in Japan and advance global phase 3 trials in gastric and pancreatic cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment